Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC trimmed its holdings in Veracyte, Inc. (NASDAQ:VCYTFree Report) by 3.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,072 shares of the biotechnology company’s stock after selling 698 shares during the period. Orion Portfolio Solutions LLC’s holdings in Veracyte were worth $555,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in VCYT. Dark Forest Capital Management LP bought a new stake in shares of Veracyte in the 3rd quarter valued at approximately $506,000. ARK Investment Management LLC lifted its holdings in shares of Veracyte by 0.8% in the fourth quarter. ARK Investment Management LLC now owns 7,655,603 shares of the biotechnology company’s stock valued at $210,606,000 after buying an additional 62,011 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Veracyte by 5.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,372,703 shares of the biotechnology company’s stock valued at $92,787,000 after buying an additional 161,073 shares during the period. Diversified Trust Co lifted its holdings in shares of Veracyte by 4.0% during the fourth quarter. Diversified Trust Co now owns 14,810 shares of the biotechnology company’s stock valued at $407,000 after purchasing an additional 575 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its holdings in shares of Veracyte by 55.5% during the third quarter. Qube Research & Technologies Ltd now owns 166,732 shares of the biotechnology company’s stock valued at $3,723,000 after purchasing an additional 59,484 shares during the last quarter.

Insider Activity

In other news, Director Muna Bhanji sold 1,539 shares of Veracyte stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $21.00, for a total value of $32,319.00. Following the completion of the sale, the director now directly owns 26,975 shares of the company’s stock, valued at approximately $566,475. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Muna Bhanji sold 1,539 shares of Veracyte stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $21.00, for a total value of $32,319.00. Following the completion of the sale, the director now directly owns 26,975 shares of the company’s stock, valued at approximately $566,475. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Karin Eastham sold 10,000 shares of Veracyte stock in a transaction on Monday, April 1st. The shares were sold at an average price of $21.65, for a total value of $216,500.00. Following the completion of the sale, the director now directly owns 33,125 shares of the company’s stock, valued at $717,156.25. The disclosure for this sale can be found here. Insiders own 1.30% of the company’s stock.

Veracyte Stock Performance

Veracyte stock opened at $21.81 on Thursday. Veracyte, Inc. has a one year low of $18.61 and a one year high of $30.52. The business has a 50 day simple moving average of $20.83 and a 200 day simple moving average of $23.71.

Veracyte (NASDAQ:VCYTGet Free Report) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.17. Veracyte had a negative return on equity of 1.42% and a negative net margin of 18.16%. The firm had revenue of $96.84 million during the quarter, compared to analysts’ expectations of $93.35 million. During the same period last year, the firm posted ($0.11) EPS. The business’s revenue was up 17.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Veracyte, Inc. will post -0.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Morgan Stanley dropped their price target on Veracyte from $22.00 to $21.00 and set an “underweight” rating on the stock in a research report on Monday, February 26th. Needham & Company LLC lowered their price objective on Veracyte from $33.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. The Goldman Sachs Group decreased their target price on Veracyte from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, April 15th. Finally, William Blair restated an “outperform” rating on shares of Veracyte in a research note on Friday, February 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $27.50.

Check Out Our Latest Research Report on VCYT

Veracyte Profile

(Free Report)

Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.

Further Reading

Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYTFree Report).

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.